Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

[Editor's note: This is part two of a two-part story; part one appeared in PharmAsia News, March 4, 2011.]

You may also be interested in...



Actavis Divests In China But Looking For Acquisition; CEO Says Pfizer’s Established Products Division Possible

Actavis is pulling out of China because its business there is too small and complicated considering the investment of time and capital that could be better spent elsewhere But it could re-enter via a sizeable acquisition, such as Pfizer’s Established Products division.

Roche Global Head Of Partnering Sophie Kornowski-Bonnet On Finding Innovation In Asia (Part 2 of 2)

In an exclusive interview, Sophie Kornowski-Bonnet sits down with PharmAsia News to share her impressions of innovation in China and the company’s overall partnering strategy in China and emerging markets.

Roche Global Head Of Partnering Sophie Kornowski-Bonnet On Finding Innovation In Asia (Part 1 of 2)

Sophie Kornowski-Bonnet sits down with PharmAsia News to share her impressions of innovation in China and the company’s overall partnering strategy in China and emerging markets.

Related Content

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel